

EVEON is announcing a partnership with a pharmaceutical laboratory based on the Intuity® Ject medical device

Grenoble, 5 February, 2019 – EVEON, designer and manufacturer of smart medical devices for the preparation and administration of drugs, is announcing that it has forged a partnership with a pharmaceutical laboratory for a development based on the innovative Intuity® Ject medical device, recipient of a 2017 Pharmapack Award¹.

Intuity® Ject is the only fully automated medical device for reconstitution and administration of lyophilised biological drugs from a vial. This medical device is intended for all biological products, including viscous products, whether in dry or liquid form, for subcutaneous or intramuscular injection. Intuity® Ject offers a unique, safe, and automatic alternative for simple and precise preparation and injection.

In February 2017, the Intuity® Ject device received the award for best innovation from Pharmapack Europe, with the mention *Ease of use and patient compliance*. One of EVEON's priorities with this device is to meet the current efficiency challenges of the healthcare system: keeping patients at home, safety and ease of use, improvement of treatment adherence, injection precision, and patient connectivity for better monitoring by healthcare professionals.



Intuity® Ject is at the heart of developments within the framework of the partnership announced today with a pharmaceutical laboratory: an automatic device for reconstitution and injection of a lyophilised drug. Ergonomics, ease of use, and connectivity are all key features in the product's design.

This agreement is the outcome of the JBT HubUp alliance², announced in November 2017, which brings together seven companies, including EVEON, and provides members of the medical and pharmaceutical industry with a unique solution for developing innovative medical devices by gathering together, in the early stages of a project, the professional skills needed to reach all of the goals: including design, manufacturing, assembly, and qualification.

"We are proud to work on an extensive subject that is at the heart of our goals: a connected automatic device for reconstitution and injection in the home care setting. For several months, our teams have been mobilised around this technological challenge, working in synergy with the teams of the JBT HubUp alliance in order to meet our client's requirements", said Vincent Tempelaere, CEO of EVEON.

¹ Press release published on 2 February 2017, for more information, visit www.eveon.eu

² The seven member companies of the JBT HubUp alliance are: JBT Group, EVEON, R&D Project Managing, Sibaya BCPHarMed, ICM Automation, OPIA Technologies, and PROGRESS Silicones. Press release published on 27 February 2017, for more information, visit www.jbt-hubup.com



About EVEON

EVEON strives to become the international leader in the automatic preparation and delivery of therapeutic treatments to improve patient quality of life.

As a partner of healthcare players, EVEON designs and manufactures technological, digital and user innovation products and services.

Forward looking, EVEON places at the heart of its commitments social values of high standards that meet the challenges of personalized and participative medicine.

EVEON focuses on business partnerships with a collaborative spirit of transparency and openness. EVEON develops a strategy based on ethical values of performance and adaptability to the needs of its clients.

EVEON will be at Pharmapack Europe, trade show in Paris (France), On 6 and 7 February, 2019, stand K61.

Press contact: Charlotte Reverand | +33 476 414 833 | cre@eveon.eu

For more information, visit: www.eveon.eu